Dataset Information

Superoxide dismutase 2 gene and cancer risk: evidence from an updated meta-analysis.

ABSTRACT: Superoxide dismutase, one of the antioxidant enzymes, plays an important role in defense against reactive oxygen species. Many previous studies reported the association between SOD2 polymorphism and the cancer risk but the results were divergent. Therefore, we performed a meta-analysis to investigate the association between SOD2 polymorphism and the cancer susceptibility. We searched in Electronic database including Pubmed, Embase, google of scholar, and Korean Studies Information Service System (KISS) for this meta-analysis. Odds ratio (OR), 95 confidence interval (CI), and p value were calculated to evaluate the relation between SOD2 polymorphism and risk of cancer using Comprehensive Meta-analysis software (Corporation, NJ, USA). The fifty-two studies including 26,865 cancer cases and 32,464 control subjects were analyzed for meta-analysis. Our meta-analysis revealed that SOD2 polymorphism statistically increased or decreased the susceptibility of cancer. In the present study, we could find that SOD2 polymorphism was related to the development of non-Hodgkin lymphoma, lung cancer, and colorectal cancer. It suggested that SOD2 polymorphism might be a candidate marker of cancer.

SUBMITTER: Kang SW

PROVIDER: S-EPMC4658836 | biostudies-other | 2015

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

Superoxide dismutase 2 gene and cancer risk: evidence from an updated meta-analysis.

Kang Sang Wook SW

International journal of clinical and experimental medicine 20150915 9

Superoxide dismutase, one of the antioxidant enzymes, plays an important role in defense against reactive oxygen species. Many previous studies reported the association between SOD2 polymorphism and the cancer risk but the results were divergent. Therefore, we performed a meta-analysis to investigate the association between SOD2 polymorphism and the cancer susceptibility. We searched in Electronic database including Pubmed, Embase, google of scholar, and Korean Studies Information Service System ...[more]

PMID: 26628947

Similar Datasets

Project description:BackgroundThe association between TP53 R72P and/or MDM2 SNP309 polymorphisms and hepatocellular carcinoma (HCC) risk has been widely reported, but results were inconsistent. To clarify the effects of these polymorphisms on HCC risk, an updated meta-analysis of all available studies was conducted.MethodsEligible articles were identified by search of databases including PubMed, Cochrane Library, EMBASE and Chinese Biomedical Literature database (CBM) for the period up to July 2013. Data were extracted by two independent authors and pooled odds ratio (OR) with 95% confidence interval (CI) was calculated. Metaregression and subgroup analyses were performed to identify the source of heterogeneity.ResultsFinally, a total of 10 studies including 2,243 cases and 3,615 controls were available for MDM2 SNP309 polymorphism and 14 studies containing 4,855 cases and 6,630 controls were included for TP53 R72P polymorphism. With respect to MDM2 SNP309 polymorphism, significantly increased HCC risk was found in the overall population. In subgroup analysis by ethnicity and hepatitis virus infection status, significantly increased HCC risk was found in Asians, Caucasians, Africans, and HCV positive patients. With respect to TP53 R72P polymorphism, no significant association with HCC risk was observed in the overall and subgroup analyses. In the MDM2 SNP309-TP53 R72P interaction analysis, we found that subjects with MDM2 309TT and TP53 Pro/Pro genotype, MDM2 309 TG and TP53 Arg/Pro genotype, and MDM2 309 GG and TP53 Pro/Pro genotype were associated with significantly increased risk of developing HCC as compared with the reference MDM2 309TT and TP53 Arg/Arg genotype.ConclusionsWe concluded that MDM2 SNP309 polymorphism may play an important role in the carcinogenesis of HCC. In addition, our findings further suggest that the combination of MDM2 SNP 309 and TP53 Arg72Pro genotypes confers higher risk to develop HCC. Further large and well-designed studies are needed to confirm this association.

Project description:BackgroundGrowing body of evidence suggest the association between SNP - 11377 C > G and SNP + 276 G > T polymorphisms of adiponectin gene with type 2 diabetes (T2D). However, these findings have not been conclusive and consistent. The present study quantitatively evaluates the data on the association between DIPOQ - 11377C/G, and + 276G/T polymorphisms and risk of T2D through a meta-analysis.MethodsA systematic search was performed in the PubMed, Web of science, Scopus and Cochrane library databases to extract published studies according to the inclusion criteria. Among the 741 studies, 391 of them were screened as full text and 31 studies were finally included in the meta-analysis. Analysis of data was performed using random-effects model. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to analyze the strength of association. Subgroup and meta-regression analyses were performed to identify the potential source of heterogeneity.ResultsThe pooled analysis showed that there was no statistically significant association between genotypes of CC (OR = 0.76, 95% CI: 0.53-1.09, P = 0.14), CG (OR = 0.93, 95% CI: 0.72-1.20, P = 0.58) and GG (OR = 1, 95% CI: 0.80-1.26, P = 0.94) ADIPO - 11377 polymorphism with increased risk of T2D. In addition, the results revealed a trend toward an increased risk of T2D for the SNP + 276 TT genotype (OR = 0.87, 95% CI: 0.77-0.98, P = 0.026) as compared with the GT and GG genotypes. Subgroup analysis by ethnicity indicated significant association between the TT genotype of the SNP + 276 and increased risk of T2D among Europeans. Met-regression demonstrated significant association between the GT genotype of + 276 polymorphism with risk of T2D in male individuals (slope: 0.0006; 95% CI: 0.0002-0.0009; P < 0.001).ConclusionsCollectively, our findings demonstrated a positive association between ADIPOQ + 276 G > T polymorphism with increased risk of T2D in male individuals with European ethnicity.

Project description:The manganese superoxide dismutase (MnSOD) gene encodes an antioxidant enzyme (SOD2) that may protect cells from oxidative damage. The MnSOD allele with Val as amino acid 16 encodes a protein that has 30-40% lower activity compared with the MnSOD Ala variant, hence possibly increasing susceptibility to oxidative stress. On the other hand, some epidemiologic studies suggest that the Ala allele is associated with a higher risk of cancer, including prostate cancer.We conducted a nested case-control study in the Health Professionals Follow-up Study with 612 incident prostate cancer cases and 612 matched controls to investigate the role of the MnSOD gene Ala16Val polymorphism and its joint association with plasma carotenoid concentrations in relation to risk of total prostate cancer and aggressive prostate cancer (advanced stage or Gleason sum > or =7).The allele frequencies in the controls were 49.8% for Ala and 50.2% for Val. No association was found between the MnSOD genotype and risk of total and aggressive prostate cancer. Furthermore, no statistically significant interaction was observed between the MnSOD genotype and any of the plasma carotenoids in relation to risk of total and aggressive prostate cancer. In analyses in which we combined data from plasma and dietary carotenoids and created a quintile score to reflect long-term carotenoid status, a 3-fold [95% confidence interval: 1.37-7.02] increased risk of aggressive prostate cancer was observed among men with the Ala/Ala genotype in the presence of low long-term lycopene status (P-value, test for interaction = 0.02) as compared with men with the Ala/Val+Val/Val genotypes with low long-term lycopene status.In this cohort of mainly white men, the MnSOD gene Ala16Val polymorphism was not associated with total or aggressive prostate cancer risk. However, men with the MnSOD Ala/Ala genotype who had low long-term lycopene status had a higher risk of aggressive prostate cancer compared with individuals with the other genotypes. These results are consistent with findings from earlier studies that reported when antioxidant status is low, the MnSOD Ala/Ala genotype may be associated with an increased risk of aggressive prostate cancer.

Dataset Information

Superoxide dismutase 2 gene and cancer risk: evidence from an updated meta-analysis.

Publications

Superoxide dismutase 2 gene and cancer risk: evidence from an updated meta-analysis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets